Is Allogene Therapeutics, Inc. (ALLO) a Buy, Sell, or Hold?
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$1.85 USD
-$0.08 (-4.15%)
- Volume
- 5.49M
- Average Volume
- 11.78M
- Market Capitalization
- $451.16M
- P/E Ratio
- -2.40
- Dividend Yield
- 0.00%
- Price Target
- $6.43
- Year High
- $4.46
- Year Low
- $0.98
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.65
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | David D. Chang |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALLO |
| CUSIP | 019770106 |
| CIK | 0001737287 |
| Web | https://www.allogene.com |
| Phone | 650 457 2700 |
| Currency | USD |
| Employees | 152 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.29 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.65 |
| Quick Ratio | 9.65 |
| Cash Ratio | 1.07 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.46 |
| Price / Cash Flow | -4.12 |
| Price / Book | 1.59 |
Price Target and Rating
| Average Stock Price Forecast | $6.43 |
| High Stock Price Forecast | $9.00 |
| Low Stock Price Forecast | $3.85 |
| Forecast Upside/Downside | -71.21% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 30 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.87 |
| Trailing P/E Ratio | -2.40 |
| PEG Ratio | -0.05 |
| P/E Growth | -0.05 |
| Net Income | $-190.89M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -56.45% |
| Return on Assets | -43.88% |
Financials Score
| AltmanZ Score | -5.54 |
| Piotroski Score | 1.00 |
| Working Capital | 244.96M |
| Total Assets | 395.96M |
| Ebit | -172.54M |
| Market Cap | 471.89M |
| Total Liabilities | 117.08M |
Poll Results
About Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R lar ... ge B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
2026-07-04 10:10:17
Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329's early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering.
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
2026-06-12 12:31:09
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics Announces Planned CEO Succession
2026-05-28 17:02:00
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Dr. David Chang, M.D., Ph.D., will transition from his role as President and Chief Executive Officer, effective June 30, 2026, following eight years of leadership that established Allogene as a leader in the development of off-the-shelf cell therapies. Dr. Chang will continue to serve on the Company's Board of Directors.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
2026-05-26 08:30:00
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conferences.
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
2026-05-14 11:21:21
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
2026-05-14 09:20:55
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
2026-05-14 07:50:53
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Allogene Therapeutics Q1 Earnings Call Highlights
2026-05-13 20:15:16
Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April financing.
Frequently Asked Questions
-
What is the current Allogene Therapeutics, Inc. (ALLO) stock price?
-
Allogene Therapeutics, Inc.(NASDAQ:ALLO) stock price is $1.85 in the last trading session. During the trading session, ALLO stock reached the peak price of $4.46 while $0.98 was the lowest point it dropped to. The percentage change in ALLO stock occurred in the recent session was --4.15% while the dollar amount for the price change in ALLO stock was -$-0.08.
-
ALLO's industry and sector of operation?
-
The NASDAQ listed ALLO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALLO?
-
David D. Chang | Co-Founder & Director
Zachary J. Roberts | President, CEO & Director
Earl Douglas | Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary
Annie Yoshiyama | SVP & Corporate Controller
Arie S. Belldegrun | Co-Founder & Executive Chairman -
How many employees does ALLO have?
-
Number of ALLO employees currently stands at 152. ALLO operates from 210 East Grand Avenue, South San Francisco, CA 94080, US.
-
Link for ALLO official website?
-
Official Website of ALLO is: https://www.allogene.com
-
How do I contact ALLO?
-
ALLO could be contacted at phone #650 457 2700 and can also be accessed through its website. ALLO operates from 210 East Grand Avenue, South San Francisco, CA 94080, US.
-
How many shares of ALLO are traded daily?
-
The average number of ALLO shares traded daily for last 3 months was 11.78M.
-
What is the market cap of ALLO currently?
-
The market value of ALLO currently stands at $451.16M with its latest stock price at $1.85